NFKB1 and lung carcinoma: Celecoxib has also recently been shown to decrease the activation of the transcription factor NFκB in lung cancer cell lines (Shishodia et al, 2004); celecoxib was found to interfere with the tumour necrosis factor-alpha (TNF-α) induced interaction of AKT with IKK (the protein kinase required for NFκB activation).